Modified immune cells tested as potential Game-Changer for severe scleroderma
NCT ID NCT06792344
Summary
This early-stage study is testing a new type of treatment called CAR-T cell therapy for children and young adults with severe, hard-to-treat scleroderma. Doctors will collect a patient's own immune cells, modify them in a lab to target a protein called CD19, and then infuse them back. The main goal is to see if this approach is safe and if it can reduce skin thickening and other symptoms of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 0571, China
Contact
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310053, Christmas Island
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.